Transcranial magnetic stimulation reduces pain and analgetic use in breast cancer patients

The effect of transcranial magnetic stimulation on pain intensity and opioid use in breast cancer patients and on serum beta-endorphin levels: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13972712

Enrollment

Registered

2023-03-17

Start date

2022-04-13

Completion date

Unknown

Last updated

2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain in breast cancer patients Signs and Symptoms

Interventions

The P1 group received 10-Hz transcranial magnetic stimulation for 20 minutes, at 80% of the motor threshold, with 100 pulses/train to 20 pulses/session, and with a 50-second intertrain interval. A fig

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. 19–60 years old 2. Used analgesics combined with opioids for pain 3. Agreed to enrol in the study

Exclusion criteria

Exclusion criteria: 1. Current chemotherapy treatment containing alkaloids vinca, taxane, platinum-based preparations 2. Electrodes implanted inside the head 3. Cochlear implants 4. History of head trauma, seizure, or syncope 5. Brain lesions 6. On drug withdrawal 7. Pregnant during the study period 8. Patient left the study 9. Insufficient blood samples for evaluating serum beta-endorphins obtained

Design outcomes

Primary

Measure	Time frame
Measured at baseline and after five sessions: 1. Pain intensity measured using a numerical rating scale (NRS) from 0-10 2. Opioid usage recorded using medical records 3. Serum beta-endorphin level measured using enzyme-linked immunosorbent assay (ELISA) kit for beta-endorphin	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Indonesia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026